Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study
published in: Hematological Oncology
date of publication: 2016-08-17
language: English
main subject: central nervous system lymphoma, rituximab, methotrexate
Cites articles 28
Date
Title
Article - wd:Q39484584